glp-1 semaglutide compound The market for compounded GLP-1

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

While preliminary research suggests promising mechanisms of action, BPC-157 remains largely in the preclinical stage, with only a handful of small human trials published to date

The Medicare GLP-1 Bridge Program is a temporary demonstration project that expands access to anti-obesity medications for Medicare beneficiaries

Astrocyte-derived TNF and glutamate critically modulate microglia activation by methamphetamine